Results 121 to 130 of about 66,706 (287)

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Use of a Bioinformatics‐Based Toxicity Scoring System to Assess Serotonin Burden and Predict Population‐Level Adverse Drug Events from Concomitant Serotonergic Drug Therapy

, 2019
Vaughn L. Culbertson, Shaikh Emdadur Rahman, Grayson C. Bosen, Matthew L. Caylor, Dong Xu   +4 more
openalex   +2 more sources

Trends in the Use of Benzodiazepines, Z-Hypnotics, and Serotonergic Drugs Among US Women and Men Before and During the COVID-19 Pandemic [PDF]

, 2021
Sadaf Arefi Milani, Mukaila A. Raji, Lu Chen, Yong‐Fang Kuo   +3 more
openalex   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

British Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman, Christopher J. Black, Andrea Shin, Daniel Keszthelyi   +3 more
wiley   +1 more source

Respiratory dysfunction and fatal apnea during pilocarpine‐induced status epilepticus

Epilepsia, EarlyView.
Abstract Objective Status epilepticus (SE) is second only to sudden unexpected death in epilepsy as a cause of seizure‐related mortality. The progression of respiratory dysfunction during experimental SE remains poorly characterized. We investigated how pilocarpine‐induced SE affects respiration in mice.
Chengsan Sun, Rachel Spera, John M. Williamson, Suchitra Joshi, Bhavya Guduru, Harini Ganabady, Jaideep Kapur   +6 more
wiley   +1 more source

Effective Treatment With Olanzapine for Burning Mouth Syndrome With Denture Intolerance in an Older Patient: A Case Report

Gerodontology, EarlyView.
ABSTRACT Introduction Burning mouth syndrome (BMS) is occasionally accompanied by denture intolerance. Case Presentation An 80‐year‐old woman with complaints of residual and relapsed intraoral pain and denture intolerance due to BMS was improved by olanzapine without severe adverse events, and her eating ability was successfully restored.
Motoko Watanabe, Masanao Inokoshi, Chizuko Maeda, Chihiro Takao, Risa Tominaga, Yasuyuki Kimura, Takahiko Nagamine, Akira Toyofuku   +7 more
wiley   +1 more source

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective/Background This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long‐term, open‐label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug–device combination of 5.2 mg dihydroergotamine in a single‐use nasal delivery device for the ...
Jessica Ailani, Larry Charleston IV, Shannon Strom, Detlef Albrecht, Robert Cowan   +4 more
wiley   +1 more source

Annual Research Review: Neural mechanisms of eating disorders in youth – from current theory and findings to future directions

Journal of Child Psychology and Psychiatry, EarlyView.
Eating disorders are prevalent and profoundly debilitating psychiatric conditions with multifactorial etiology that frequently manifest during adolescence. This developmental stage is characterized by significant neurostructural and neurofunctional change, which may create a context conducive to the emergence of eating pathology.
Kelsey Hagan, E. Caitlin Lloyd, Sasha Gorrell   +2 more
wiley   +1 more source

Association of prenatal antidepressant use with internalizing behaviors from kindergarten to adolescence

Journal of Child Psychology and Psychiatry, EarlyView.
Background To examine, using repeated measures, whether prenatal serotonin/norepinephrine reuptake inhibitor (SRI) antidepressant exposure is associated with increased anxious behaviors at kindergarten age and anxiety and/or depression behaviors after kindergarten and into adolescence.
Amanda S. Nitschke, Paramdeep Kaur, Naomi Phagau, Helena Abreu do Valle, Jeffrey N. Bone, Brenda Poon, Martin Guhn, Simone N. Vigod, Tim F. Oberlander, Gillian E. Hanley   +9 more
wiley   +1 more source